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Abstract 
Lycopene, a compound that blocks the action of free radicals and oxygen molecules, 
is found in tomatoes and tomato-based products and linked to a reduced incidence of cancer. 
Increasing willingness of patients to maintain a healthy lifestyle by supplemental intake of 
nutrients and acceptance of alternative therapeutics has boosted research into 
nutraceuticals. Lycopene´s potential to prevent or treat cancer has been investigated, but 
outcomes are inconsistent and its mode of action is still unknown. Further studies are needed 
to understand the role of lycopene in cancer prevention and treatment. The impact of 
lycopene on viability, proliferation, migration, and invasion of five different cancer cell lines 
was determined using monolayer and spheroid cultures. Cell viability was significantly 
reduced upon lycopene treatment at physiologically attainable concentrations. Cell 
proliferation, migration, and invasion did not change upon lycopene treatment. Ovarian 
cancer spheroids initially showed a decreased proliferation and after 14 days increased cell 
viability upon lycopene treatment, confirming the potential of lycopene to reduce cancer cell 
growth in short-term cultures and indicate also enhanced cell viability over prolonged 
exposure. This study cannot substantiate that lycopene inhibits cell functions associated with 
tumor growth; even in a 3D cancer model that mimics the natural tumor microenvironment.     
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Introduction 
A balanced diet, following the rule of consuming five portions of fruit and vegetables 
per day, has been associated with a reduced incidence of diseases, such as cancer and 
coronary heart disease [1, 2]. While a high intake of animal fat, milk, and red meat seems to 
increase cancer risk, a diet rich in antioxidants, present in fruits and vegetables, is discussed 
to have chemo-preventive effects against breast, prostate, and ovarian cancer [2, 3]. This 
has also been shown for the intake of vitamins like vitamin E, beta-carotene or lycopene [4]. 
Antioxidants are known to reduce oxidative stress and DNA damage by inactivating free 
radicals. Furthermore, they are capable to selectively induce apoptosis in malignant cells, 
while, at the same time, sparing healthy cells [5]. 
Containing a big variety of biologically active ingredients, most of these fruits and vegetables 
have a long history in the use as traditional medicines [6]. Steadily increasing sales figures of 
dietary or food supplements have resulted in an increased interest of the scientific community 
in the chemo-preventive potential of specific nutrients [3]. In 1989, Stephen DeFelice created 
the term “nutraceutical” by combining “nutrition” and “pharmaceutical” [7]. According to his 
definition, a nutraceutical is “a food, or part of a food, that provides medical or health benefits, 
including the prevention and/or treatment of a disease” [8]. Unlike dietary supplements, a 
nutraceutical has the function, besides supplementing the diet, to prevent or treat diseases 
[7]. Within this context, the interest in lycopene-rich diets and supplements for the prevention 
or therapy of different tumor entities, such as breast, prostate, and ovarian cancer, has 
increased during the last years. 
Lycopene, naturally occurring in many fruits and vegetables like tomatoes, papaya, 
watermelon or pink grapefruit, belongs to the group of carotenoids. It is highly potent towards 
oxygen in terms of overall capacity in inactivating free radicals within an organism. Its 
antioxidant properties are suggested to play a fundamental role in the prevention of cancer 
and other chronic diseases [9]. Besides vitamins D and E as well as selenium and green tea 
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polyphenols, lycopene is suggested to be one of the most promising natural anti-cancer 
compounds [3]. Prevention of oxidative DNA damage in tumor cells, decrease of tumor cell 
proliferation, reduction of migratory and invasive behavior as well as induction of apoptosis 
are only a few of the discussed potential mechanisms of lycopene [9]. However, due to 
inconsistencies in experimental, preclinical and clinical study outcomes and an unknown 
mode of action, it is still questionable if there is a clear evidence to recommend the 
supplemental intake of lycopene to patients in addition to a well-balanced diet. The American 
Institute for Cancer Research (AICR) classifies lycopene as a compound that shows limited 
evidence for cancer prevention, and therefore, the AICR is not conclusive in its 
recommendation regarding supplemental lycopene intake. However, the AICR clearly states 
that lycopene-containing food remains important to maintain a healthy, cancer-protective diet 
[10]. 
The aim of this study was to investigate the anti-proliferative, anti-migratory and anti-invasive 
properties of lycopene on classical monolayer cultures, using different breast, prostate, and 
ovarian cancer cell lines; belonging to the group of hormone-dependent cancer entities. As a 
proof of concept, the impact of lycopene on viability and proliferation of two different ovarian 
cancer cell lines grown in spheroid cultures was examined, as they reflect a physiologically 
relevant model to study the behavior of cancer cells within their natural tumor 
microenvironment. To our knowledge, this is the first study to test the effects of lycopene on 
ovarian cancer cells using a three-dimensional (3D) cell culture approach.     
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Methods 
 Cell culture. MDA-MB-231 breast cancer, PC-3 and LNCaP prostate cancer, and 
SKOV-3 ovarian cancer cells were obtained from the American Type Culture Collection 
(ATCC; Manassas, VA, USA). MDA-MB-231 cells were derived from a pleural effusion of a 
metastatic adenocarcinoma of the mammary gland. PC-3 cells were isolated from a grade IV 
adenocarcinoma of the prostate. LNCaP cells were derived from a metastatic site of a 
carcinoma of the prostate. SKOV-3 cells were isolated from ascites of an adenocarcinoma of 
the ovary. OV-MZ-6 ovarian cancer cells were established from malignant ascites drained 
from a patient with an advanced cystadeno-carcinoma as previously published [11]. MDA-
MB-231 cells were cultured in high glucose Dulbecco’s modified Eagle medium (DMEM; 
Invitrogen, Vic, Australia), supplemented with 10 % fetal bovine serum (FBS) and 1 % 
penicillin/streptomycin. PC-3, LNCaP, and SKOV-3 cells were maintained in RPMI medium 
(Invitrogen), supplemented with 5 % FBS, 100 IU/ml penicillin and 0.1 mg/ml streptomycin 
(Invitrogen). OV-MZ-6 cells were maintained in DMEM, supplemented with 10 % FBS and 1 
% penicillin/streptomycin. 
 
Preparation of lycopene solutions. A water-dispersible lycopene formulation, 
containing beadlets made up of 10 % lycopene in a matrix of carbohydrates, was provided by 
BASF (Ludwigshafen, Germany). The lycopene compound was dissolved in sterile 
phosphate-buffered saline (PBS; Invitrogen) to a final stock concentration of 1.0 mM and 
frozen to maintain stability. Treatment solutions were prepared fresh from this stock 
concentration in the respective culture media to final concentrations of 0.1, 0.5, 1.0, 5.0, and 
10.0 µM lycopene for each experiment. For the no treatment control, a solution of PBS in the 
respective culture media was prepared in the concentration equivalent to the highest 
lycopene concentration. 
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Analyses of cell viability and proliferation within monolayer cultures. The non-
cytotoxic AlamarBlue assay, a measure of the metabolic activity, was used to determine the 
cell viability upon lycopene treatment continuously over time as reported previously [12]. 
Cells were seeded in duplicates at a density of 3.0 x 103 cells/well in 100 µl culture media 
onto 96-well plates (Nunc, Rochester, NY, USA) and cultured in a humidified atmosphere for 
4, 24, 48, 72, and 96 hrs. Lycopene solutions were added 24 hrs after cell seeding at 
concentrations of 0.1, 0.5, 1.0, 5.0, and 10.0 µM in a volume of 100 µl as well as the PBS 
control. The 4 hrs time-point was used as a seeding control without treatment. As per assay 
instructions, 10 % AlamarBlue reagent (Biosource, Camarillo, CA, USA) was added to the 
culture media 4 hrs prior to being analyzed for every time-point. Fluorescent signals 
(excitation 544 nm, emission 590 nm) were detected with a fluorescence plate reader (BMG 
PolarStar, BMG LABTECH, Offenburg, Germany). The change in cell viability was assessed 
for every time-point and normalized to seeding controls. This experiment was repeated three 
times. 
The PicoGreen assay, a measure of double-stranded DNA, was used to determine the cell 
proliferation upon lycopene treatment over time as reported previously [12]. Cells cultured for 
cell viability assays were also used for PicoGreen proliferation assays (Invitrogen). As the 
non-cytotoxic AlamarBlue reagent allows for the subsequent performance of other assays 
without influencing following results [12]. AlamarBlue-containing media was discarded and 
96-well plates frozen at -80°C for at least 48 hrs. Proteinase K solution (100 µl; 0.5 mg/ml; 
Invitrogen) was added to each sample and incubated overnight at 37°C/5 % CO2, followed by 
8 hrs incubation at 65°C. A standard curve was prepared as per the manufacturer’s protocol, 
containing DNA standard concentrations from 0–2,000 ng/ml. Fluorescent signals (excitation 
480 nm, emission 520 nm) were captured using a fluorescence plate reader. The DNA 
content was calculated using the DNA standard curve for every time-point and normalized to 
seeding controls. This experiment was repeated three times. 
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Analysis of cell migration using transwell chambers. The transwell migration 
assay was performed in 12-well plates with Millicell® hanging cell culture inserts (Merck 
Millipore, VIC, Australia) with a pore size of 8.0 µm. Cells were seeded at a density of 2.0 x 
105 cells/well in serum-free media onto the cell culture insert. Lycopene was added at 
concentrations of 0.5, 1.0, 5.0, and 10.0 µM into both, the upper and the bottom, chambers, 
to avoid dilution of the compound. Ten percent FBS was added to the lower chamber as a 
chemo-attractant and cells were then cultured for 24 hrs. A PBS control was included as a 
control for random migration of cells from the upper to the bottom chamber. Then, cells 
remaining on the upper surface of the insert were removed. To quantify the number of 
migrated cells, the remaining cells on the bottom of the insert were fixed with 100 % ice-cold 
methanol and stained with 0.5 % crystal violet (Sigma-Aldrich, NSW, Australia). Absorbance 
was measured at 595 nm using a plate reader. Results were corrected for background 
staining and normalized to controls. This experiment was repeated three times. 
 
Analysis of cell invasion on Matrigel-coated chambers. Transwell invasion assays 
were performed in 12-well plates with Millicell® hanging cell culture inserts. One day prior to 
cell seeding, inserts were coated with 100 µl/well of growth factor-reduced Matrigel (Sigma-
Aldrich). Cell seeding was performed as per cell migration assays as described above, and 
cells were cultured for 48 hrs. To quantify the number of invaded cells, cells on the bottom of 
the insert were fixed with 100 % ice-cold methanol and stained with 0.5 % crystal violet. 
Absorbance was detected at 595 nm using a plate reader. Results were corrected for 
background staining and normalized to controls. This experiment was repeated three times. 
 
Preparation of gelatine-methacrylamide-sodium hyaluronate-based hydrogels. 
Gelatine-methacrylamide (GelMa) was synthesized from gelatine (Sigma-Aldrich) and 
methacrylic anhydride (Sigma-Aldrich) as described previously [13-15]. Briefly, GelMa 
polymer was mixed with PBS to obtain a 5 % concentration with the extracellular matrix 
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(ECM) component sodium hyaluronate (HA; 0.1 %; Lifecore Biomedical, Chaska, MN, USA) 
and cross-linked to GelMa-HA-based hydrogels by UV-irradiation using 0.5 mg/ml of Irgacure 
2959 photoinitiator (BASF). This 3D culture model was used to grow ovarian cancer cells 
within a 3D microenvironment as spheroids as reported before [13]. Therefore, 2.8 x 105 
cells/1 ml GelMa-HA solution were cross-linked and separated into single hydrogels 
containing 1.12 x 104 cells/hydrogel. Treatment was carried out using two different regimes - 
lycopene treatment (0.5 and 5.0 µM) starting on day 1 to day 14 and lycopene treatment (0.5 
and 5.0 µM) from day 7 to day 14 (0.5 and 5.0 µM) - and no treatment controls. Lycopene 
was added to the 3D cultures fresh every 48 hrs in combination with media changes. Each 
treatment regime was carried out using 5 different hydrogels. 
 
Analyses of cell viability and proliferation in spheroid cultures. AlamarBlue cell 
viability assays were performed on days 1, 7, and 14 as reported [16]. Briefly, 4 % 
AlamarBlue reagent was added to the culture media 6 hrs prior to being analyzed for every 
time-point and fluorescent signals captured using a fluorescence plate reader (excitation 544 
nm, emission 590 nm). After reading AlamarBlue fluorescent signals, hydrogels were 
transferred into PBS until the AlamarBlue reagent diffused out of the hydrogels to perform 
PicoGreen proliferation assays. Colorless hydrogels were frozen at -80°C for at least 48 hrs. 
Following proteinase K treatment (0.5 mg/ml) overnight at 65°C, PicoGreen fluorescent 
signals (excitation 480 nm, emission 520 nm) were measured using a fluorescence plate 
reader. The DNA content was calculated using the DNA standard curve for every time-point 
and normalized to controls. This experiment was repeated three times. 
 
Confocal laser scanning microscopy of spheroid cultures. After 14 days of 3D 
culture, hydrogels were washed with PBS and fixed with 4 % paraformaldehyde as reported 
[16]. Samples were permeabilized with 0.2 % Triton-X-100, washed with 0.1 M glycine in 
PBS, then with PBS prior to rhodamine415-conjugated phalloidin (0.3 U/ml; Invitrogen) and 
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4,6-diamidino-2-phenylindole (2.5 mg/ml; Invitrogen) staining for 1 h each. Two different 
hydrogels for each treatment regime were analyzed with a Nikon A1R confocal laser 
scanning microscope (Nikon Corp, Tokyo, Japan). 
 
Scanning electron microscopy of spheroid cultures. After 14 days of 3D culture, 
hydrogels were fixed with 3 % glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.3) for 
1 h at 4°C, then washed in water and dehydrated in a series of ethanol as reported [16]. 
Samples were critically point-dried (Denton Vacuum, Moorestown, NJ, USA) and mounted on 
aluminium stubs. After gold-coating in a SC 500 sputter coater (Bio-Rad, Hercules, CA, 
USA), two different hydrogels for each treatment regime were examined using a Quanta 200 
scanning electron microscope (FEI, Hillsboro, Oregon, USA) operating at 10 kV. 
 
Statistical analysis. For statistical analyses, SigmaStat 3.5® software was used. Data 
were presented as mean values ± standard error of three biological replicate experiments. 
Differences between treatment regimes and the control were analyzed using a one-way 
analysis of variance (Anova), with Holm-Sidak post-hoc test. The level of significance was set 
at p<0.05.     
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Results 
Lycopene reduces the viability of cells grown in monolayer 
cultures. 
Lycopene treatment of all five cancer cell lines was performed 24 hrs after cell seeding 
to allow for cell recovery. Subsequently, cells were incubated with 0.1, 0.5, 1.0, 5.0, and 10.0 
µM lycopene for up to 72 hrs. These concentrations represent the physiological limit between 
0.1 and 2.0 µM as well as the supra-physiological doses of 5.0 and 10.0 µM to address the 
question whether further pro- or anti-tumorigenic effects can be detected. Most prominent 
effects on viability of the cancer cell types tested were observed after treatment with 0.5, 1.0, 
and 5.0 µM lycopene (Fig. 1). 
The viability of MDA-MB-231 breast cancer cells was significantly reduced after 4 hrs of 
treatment with 1.0 µM lycopene up to 19 % as compared to the no treatment control. 
Incubation with lycopene at concentrations of 0.1, 1.0, and 5.0 µM over 24 hrs led to 
significantly reduced viability up to 35 %. A significant decrease of about 20-25 % of viable 
cells was detected at concentrations ranging from 0.5 to 5.0 µM over 4, 24, and 72 hrs for 
LNCaP prostate cancer cells, reaching up to 28 % after 24 hrs exposure to 0.5 µM lycopene. 
Distinctive effects on PC-3 prostate cancer cells were detected, showing a 26 % reduced 
viability after 24 hrs treatment with 1.0 µM lycopene. This effect was also significant at 
lycopene concentrations of 0.5 and 5.0 µM after 48 and 72 hrs incubation, with a cell viability 
of 10-20 % under control levels. OV-MZ-6 ovarian cancer cells significantly responded to 0.5 
and 5.0 µM lycopene exposure with a decreased viability by 10-28 % as compared to 
controls. After 48 hrs incubation, levels declined at all concentrations by more than 30 %. 
Lycopene effects on SKOV-3 ovarian cancer cells were less pronounced, reaching up to 15 
% reduction in viability after 4 hrs with 5.0 µM lycopene. 
Interestingly, a typical u-shaped curve was observed for all cancer cell types at all 
concentrations and time-points tested (Fig. S1). Viability declined between 0.1 and 5.0 µM 
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lycopene, followed by a sharp increase after treatment with 10.0 µM lycopene. However, a 
dose of 10.0 µM cannot be achieved in human plasma by consuming lycopene-rich food or 
lycopene-based supplements. As described previously by Allen et al., concentrations up to 
2.0 µM are considered physiological [17]. Noteworthy, a non-linear dose-effect relationship 
has also been shown for other dietary compounds [18]. These findings suggest that lycopene 
overall reduces the viability of breast, prostate, and ovarian cancer cells at concentrations 
ranging from 0.5 to 5.0 µM, which is within the physiological attainable range. 
 
Lycopene has a minor impact on proliferation of cells grown in 
monolayer cultures. 
The impact of lycopene on cell proliferation was less distinct than its effects on cell 
viability (Fig. S2). A significant reduction in proliferation was only seen after 24 hrs of 
exposure to 5.0 µM lycopene in OV-MZ-6 ovarian cancer cells (22 % under control level) as 
well as after 48 hrs of treatment with 0.5 µM lycopene in MDA-MB-231 breast cancer (24 % 
under control level) and LNCaP prostate cancer cells (13 % under control level). MDA-MB-
231 breast cancer cells and PC-3 prostate cancer cells showed a slightly reduced 
proliferative behavior.. Both ovarian cancer cell lines proliferated less by an overall of 10-20 
% after 4 and 24 hrs of treatment but increased proliferation after exposure to lycopene over 
48 and 72 hrs respectively. Thus, contrary to the cell viability results, lycopene has only a 
minor impact on the proliferative behavior of the cancer cell types tested. 
 
Lycopene has no influence on migratory behavior of cells. 
Using a transwell migration assay, the impact of lycopene at dosages between 0.5 and 
10.0 µM on migration of breast, prostate, and ovarian cancer cells was determined. None of 
the cell lines tested showed any significance for an altered migratory behavior (Fig. 2). MDA-
MB-231, OV-MZ-6, and SKOV-3 cells showed a trend for reduced migration after treatment 
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with lycopene, whereas both prostate cancer cell lines tended to migrate more upon lycopene 
exposure. Overall, no evidence was found that lycopene has an impact on the migratory 
behavior of the cancer cell types tested. 
 
Lycopene influenced invasion of SKOV-3, but not OV-MZ-6 
ovarian cancer cells. 
Unlike breast and prostate tumors, ovarian cancer progresses in a unique manner. 
Ovarian cancer cells disseminate within the abdominal cavity and form multicellular spheroids 
that invade into the ECM lining the peritoneum [19]. Hence, the invasion of two different 
ovarian cancer cell lines was analysed using growth factor-reduced Matrigel in the transwell 
system. SKOV-3 cells treated with 5.0 and 10.0 µM lycopene reduced their invasion by 20 %, 
without reaching significance, and showed a slightly decreased invasive behavior at 0.5 and 
1.0 µM lycopene. OV-MZ-6 cells did not notably change their invasive behavior upon 
exposure to lycopene (Fig. 3). 
 
Effects of lycopene on viability and proliferation of ovarian 
cancer cells grown in spheroid cultures. 
To allow multicellular spheroid formation, OV-MZ-6 and SKOV-3 ovarian cancer cells 
were grown within an in vitro 3D cancer model that mimics their natural tumor 
microenvironment [13, 16]. Spheroid cultures were grown over 14 days and cell viability and 
growth investigated upon exposure to 0.5 and 5.0 µM lycopene starting on day 1, to test if 
lycopene can slow down spheroid growth and reduce spheroid formation, and starting on day 
7, to test if lycopene can affect already formed spheroids, of 3D culture. Spheroid formation 
was visible on day 7 and more pronounced after 14 days of 3D culture as shown by confocal 
laser scanning microscopy (Fig. 4) and scanning electron microscopy (Fig. 5). Viability and 
proliferation data indicate that a concentration of 5.0 µM lycopene was capable to decelerate 
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the development of cancer cell spheroids until day 7, but that 14 days of treatment reversed 
this effect, and cells responded with enhanced viability and proliferation (Figs. 4 and 6a-b). 
OV-MZ-6 cells slightly reduced proliferation and viability upon treatment with lycopene until 
day 7 but increased both parameters after 14 days of 3D culture. Proliferation of SKOV-3 
cells decreased significantly after 7 days, when treated with 0.5 µM lycopene, accompanied 
with reduced cell viability. As with the OV-MZ-6 cells, the increase in proliferation and viability 
of SKOV-3 cells after 14 days of 3D culture was insignificant (Fig. 6a). Lycopene treatment 
with 0.5 and 5 µM respectively from day 7 until day 14 resulted in increasing viability and 
proliferation, with a significant effect on viability of SKOV-3 cells (Fig. 6b). 
These findings indicate a reduction of viability and proliferation of both ovarian cancer cell 
lines grown in 3D cultures for 7 days when exposed to lycopene, but also a subsequent rise 
in viable and proliferating cells after 14 days of 3D culture. Lycopene was added to the cells 
every 48 hrs over the duration of the experiment. However, there is evidence that lycopene 
metabolites are generated very easily by initial cleavage through carotenoid monooxygenase 
II (CMO II). The antioxidant capacity of these lycopene metabolites is not entirely known yet, 
even though there is some evidence that for instance apo10`-lycopenoic acid reduced the 
proliferation of non-small cell lung cancer cells [20]. Apo10`-lycopenoic acid also inhibited cell 
growth of non-malignant bronchial epithelial and lung cancer cells [21]. It is therefore possible 
that oxidation products contributed to the lycopene effects seen in our 3D cultures.    
Discussion 
Previously published studies on lycopene and its anti-cancer effects are inconsistent 
and show great variation in their outcomes [9, 22]. This might be due to different lycopene 
sources used ranging from tomato extract or pure lycopene to water dispersible lycopene 
formulations. Additional factors that influence these study outcomes are varying solubilisation 
techniques and differences in concentrations, sometimes well above the physiological limit. 
Lycopene levels as high as 2.0 µM are detected in human plasma after consumption of 
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tomato sauce, juice and soup and are therefore considered as physiologically attainable by 
humans [17, 23]. Nevertheless, a wide range of published studies report results using supra-
physiological lycopene concentrations sometimes up to 100.0 µM [22, 24-29]. These 
differences in study design all need to be considered to reliably compare varying outcomes. 
In this study, concentrations within the physiological limit between 0.1 and 2.0 µM as well as 
the supra-physiological doses of 5.0 and 10.0 µM were tested to address the question 
whether further pro- or anti-tumorigenic effects can be detected. 
 
Commonly used metabolic assays like MTT, Trypan Blue, WST-1 or Alamar Blue have been 
employed to assess the potential of lycopene to reduce proliferation of tumor cells. However, 
as reported by Quent et al. [12], these assays are not suitable to quantify cell numbers as 
they only detect the metabolic activity of treated cells, which can change within the cell cycle. 
In this study, cell viability and proliferation measurements were distinguished by using 
AlamarBlue and PicoGreen assays, the latter measuring the DNA content and therefore cell 
numbers. Overall, treatment with lycopene at physiologically attainable concentrations 
reduced the metabolic activity of all five cancer cell types tested, resulting in decreased 
viability rates as measured by AlamarBlue. Exposure to 0.1, 1.0, and 5.0 µM lycopene over 
24 hrs reduced the viability of MDA-MB-231 breast cancer cells by up to 35 % compared to 
the no treatment control. Decreasing viability of breast cancer cells has been shown before 
by others using MCF-7 cells [28, 30]. Uppala and coworkers [31] compared carcinogenic 
MCF-7 cells with non-carcinogenic MCF-10 cells, describing an inhibitory lycopene effect on 
MCF-7 cell viability, while MCF-10 cells were unaffected, implicating that an oncogene as a 
target is present to observe the lycopene effect [31]. 
OV-MZ-6 ovarian cancer cells had a reduced viability by more than 30 % after 48 hrs 
exposure to lycopene at physiological concentrations. SKOV-3 ovarian cancer cells 
responded with a 15 % decrease in viability only after 4 hrs. So far, to our knowledge, this 
effect on ovarian cancer cell viability has not been shown in the literature before. The only in 
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vitro study examining the effect of lycopene on ovarian cancer cells reported a slightly 
reduced viability of CRL-11731 cells at a dose of 1.0 µM, with increasing rates up to 50.0 µM, 
but the latter by far exceeds the physiological limit [24]. 
The most intensively investigated cancer type in the field is prostate cancer. This study 
confirms published data by others regarding viability of LNCaP and PC-3 prostate cancer 
cells after lycopene treatment. A dose of 0.5 µM lycopene over 24 hrs decreased viability in 
LNCaP cells by up to 28 %, whereas PC-3 cells responded to 1.0 µM lycopene with a 26 % 
reduction compared to no treatment controls. Kotake-Nara et al. [32] reported an even 
greater reduction in cell viability of 58 % with 20.0 µM lycopene. This has also been observed 
by Yang and coworkers [33] using lycopene concentrations within the physiological range. 
Hwang et al. [34] incubated LNCaP cells with tomato paste extract resulting in a decrease in 
viability of more than 50 %. The authors mentioned that also other ingredients than lycopene 
could be considered for this outcome, as the extract consists of a mixture of nutrients [34]. 
The lycopene viability data reflect u-shaped curves for all cancer cell types and time-points. 
Viability decreases at concentrations between 0.1 and 5.0 µM, followed by a subsequent 
sharp rise upon 10.0 µM lycopene. The dose-response relationship between a compound 
and its measured physiological effect is of considerable importance. There is evidence that 
this dose-response relationship is not always linear for dietary compounds and that a 
protective effect, measured at lower doses, can become harmful at higher amounts. This 
study outlines these effects at concentrations that have not been measured in humans after 
consuming a lycopene-rich diet so far. Nevertheless, it is reasonable to keep in mind that 
over-excessive consumption of supplements is not always beneficial and can even switch 
from a healthy benefit to a harmful effect. 
While our viability data, showing a clear decrease in viability for all five cancer cell types after 
lycopene treatment, indicate very strongly that lycopene plays a supportive role against 
breast, prostate, and ovarian cancer cells, the proliferation results do not completely support 
this assumption. Significantly reduced proliferation rates were only observed for MDA-MB-
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231 breast cancer and LNCaP prostate cancer cells after 48 hrs treatment with 0.5 µM 
lycopene as well as for OV-MZ-6 ovarian cancer cells after 24 hrs exposure to 5.0 µM 
lycopene. Indeed, these overall results reflect a reduction in cell proliferation upon lycopene 
treatment for the cancer cell types tested, but except for the above outlined cases, there was 
no significance. Other studies report reduced proliferation of DU145 prostate cancer cells [22] 
as well as MCF-7 and MDA-MB-231 breast cancer cells [35] after treatment with lycopene at 
concentrations between 10.0 and 25.0 µM, which is again above the physiological limit [22, 
35]. Since effects on cell viability and proliferation were observed, apoptosis assays are 
currently being performed to further elucidate lycopene’s impact on cancer cell functions. 
 
Besides influencing tumor cell viability and proliferation, lycopene has also been suggested to 
exert anti-metastatic effects in highly aggressive cancers. Aggressive cancer cells have the 
capability to migrate from the primary site, invade into the surrounding tissues and promote 
angiogenesis [36]. Degrading basement membrane and ECM proteins is one key metastatic 
step, which is mediated by matrix metalloproteinases (MMP) [37]. Huang and coworkers [38] 
reported a lycopene-induced inhibition of migration and invasion of SK-Hep-1 hepatocellular 
carcinoma cells at a dose of 5.0 µM, accompanied by up-regulation of the metastasis 
suppressor gene nm23-H1. Moreover, in another study conducted by this group this led to 
reduced MMP-9 expression and activity in SK-Hep-1 cells upon lycopene exposure [36]. Lin 
et al. [39] showed a reduced invasive behavior of HT-29 colon cancer cells, with suppressed 
expression of MMP-7 at lycopene concentrations between 0.1 and 2.0 µM [39]. In addition, 
Bureyko and co-workers [40] found a decrease in α2β1 integrin expression in 22Rv1, LNCaP 
and PC-3 prostate cancer cells upon treatment with 10.0 µM lycopene [40]. In contrast, in this 
study, migration of LNCaP and PC-3 cells was not reduced. A slightly decreased migration 
was observed in MDA-MB-231 breast cancer cells without reaching significance. Migration 
and invasion of OV-MZ-6 ovarian cancer cells was not affected by lycopene treatment. 
SKOV-3 ovarian cancer cells migrated and invaded slightly less upon lycopene treatment 
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without being significant. These results do therefore not confirm the capability of lycopene to 
inhibit migration and invasion in the different cancer cell types tested. 
 
Over the past decade, 3D cell culture approaches have become increasingly important for in 
vitro and in vivo studies, particularly in the field of cell biology. These 3D models have been 
developed to overcome the limitations of traditional monolayer cultures, thereby mimicking 
the 3D tissue architecture and natural microenvironment [41]. They provide a powerful 
toolbox to study cancer cell biology and the tumor’s interaction with its niche, and thus, a test 
system to investigate anti-cancer targets. The tumor’s microenvironment and the properties 
of the surrounding ECM have a clear impact on specific behaviors of cancer cells, such as 
proliferation, invasion and the potential to undergo apoptosis [42]. Therefore, 3D cancer 
models gradually replace monolayer drug screening strategies in order to achieve a faithful 
mimic of the 3D structure and signaling milieu in which the cancer cells reside within patients 
[16]. In this study, a GelMa-based hydrogel was used, in which HA was incorporated as a 
representative ECM component, to allow spheroid formation of ovarian cancer cells. This 3D 
model was not used as a direct comparison to monolayer cultures, but rather as a platform 
that is suitable to allow spheroid growth in a physiological context, thereby bridging the gap 
between in vitro and in vivo studies [13]. As a proof of concept, the impact of lycopene on 
viability and proliferation of two different ovarian cancer cell lines was examined. This 3D 
model induced spheroid formation and growth in OV-MZ-6 and SKOV-3 cells after 7 days of 
3D culture, which was more prominent at day 14. One week of lycopene treatment of SKOV-
3 cells grown within GelMa-HA-based hydrogels decreased proliferation and viability. This 
effect was already observed at a concentration of 0.5 µM, which reflects physiological levels. 
Lycopene-treated OV-MZ-6 cells showed a reduced proliferation and viability only at a dose 
of 5.0 µM. Interestingly, both ovarian cancer cell lines responded with increasing viability and 
proliferation after 14 days of 3D culture upon lycopene treatment. Lycopene was added to the 
cells every 48 hrs over the duration of the experiment. Hence, there is no reason to assume 
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that internalized levels declined over time. Both treatment regimes did not result in different 
outcomes. In this study, a lycopene beadlet formulation was used, which contains 10 % 
lycopene and 90 % carbohydrates. This high carbohydrate amount could provide an ideal 
nutrient for cancer cells as it might diffuse faster into the hydrogel than lycopene itself. 
Therefore, the increased proliferation over a prolonged treatment period might be attributed 
to the carbohydrate content in the culture media. The used control solution contained PBS 
only and no placebo beadlets. Preliminary results of 3D studies with placebo beadlets using 
PEG-based hydrogels indicate that there was no change in proliferation of OV-MZ-6 cells 
treated with control (placebo) or lycopene-containing beadlets (Fig. S3). However, there was 
a slight reduction of proliferation with both lycopene concentrations used (2 and 5 μM) over 
the entire treatment period of 14 days, indicating that the carbohydrates could indeed be a 
reason for the enhanced proliferation seen, but these results did not reach significance. 
On the other hand, the increase in proliferation after prolonged exposure times might be one 
of the reasons how lycopene exerts synergistic effects in combination with cytotoxic drugs 
[24, 43, 44]. Due to the antioxidative properties of lycopene, concerns were raised, whether 
both cancer and normal cells can be protected by this carotenoid when exposed to docetaxel 
[45]. Contrary to this assumption, Tang et al. [44] demonstrated that the combination of 
docetaxel with lycopene significantly enhanced the cancer cells’ response to the cytotoxic 
drug. Taxanes bind to β-tubulin, thereby leading to abnormalities in the function of 
microtubules and defective spindle formation during metaphase, causing cell cycle arrest and 
subsequent apoptosis [46]. Lycopene induced an increase in cell proliferation, and therefore, 
could result in enhanced accessibility of cancer cells towards chemotherapy. This assumption 
needs to be confirmed in future studies, for example by using 3D cell culture approaches. 
In conclusion, Lycopene’s preventive effects on cancer cell functions are still very 
heterogeneous. These inconsistent results arise mainly from different lycopene sources and 
solubilisers as well as the wide range of concentrations, which, in many studies, exceed 
physiologically attainable levels. For biochemical studies, usually lycopene itself as a 
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compound is tested, rather than its active metabolite, which can cause the beneficial effect in 
humans. 
The findings from this study on cell viability, measured in monolayer cultures, reflect the 
potential chemo-preventive effects of lycopene on breast, prostate, and ovarian cancer cells 
at physiological concentrations that have been found in humans after consuming a lycopene-
rich diet. However, proliferation rates, which give a more accurate idea on the actual growth 
of the cancer cells, did not decline significantly. Furthermore, this study did not explicitly show 
that lycopene prevents cancer cell migration and invasion. Using a 3D cell culture approach, 
that reflects the natural tumor microenvironment, both viability and growth of two different 
ovarian cancer cell lines were reduced after exposure to lycopene at physiological 
concentrations for 7 days. However, prolonged treatment with lycopene resulted in increasing 
cell proliferation. Whether this effect is caused by carbohydrates, a major component of the 
lycopene formulation used in this study, rather than by lycopene itself, is currently part of 
ongoing experiments. 
To date, the beneficial effects of lycopene in the human diet are evident. Supplementing the 
food intake with lycopene as a combination treatment for breast, prostate or ovarian cancer 
cannot be supported from this data. More harmonized and well-conducted in vitro and in vivo 
studies are necessary to investigate the supportive effect of supplemental lycopene in cancer 
treatment.     
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Figure legends 
Fig. 1: Viability of MDA-MB-231, LNCaP, PC-3, OV-MZ-6, and SKOV-3 cells after 
treatment with lycopene. Viability of MDA-MB-231 cells was significantly decreased after 
exposure to 0.1, 1.0 and 5.0 µM lycopene after 24 hrs. LNCaP cells responded with 
significantly reduced viability rates after 4, 24, and 72 hrs of treatment. PC-3 cells also 
showed an explicit drop in viability, especially at 1.0 and/or 5.0 µM concentrations at all time-
points. A distinct reduction in viability was seen in OV-MZ-6 cells after 24 and 48 hrs 
exposure to 0.5 and 5.0 µM lycopene. Interestingly, SKOV-3 cells were relatively unaffected 
by treatment with lycopene. Dashed lines represent no treatment controls. Asterisks indicate 
p<0.05. 
 
Fig. 2: Influence of lycopene on migration rates of MDA-MB-231, LNCaP, PC-3, OV-MZ-
6, and SKOV-3 cells. MDA-MB-231 cells responded at 0.5 and 0.1 µM with a reduced 
migrative behavior; however, this was not significant. Migration rates of LNCaP and PC-3 
cells increased upon exposure to all lycopene concentrations without reaching significance. 
OV-MZ-6 cells responded with slightly reduced migration at lower concentrations, which 
increased at higher levels. SKOV-3 cells were relatively unaffected at all doses. Dashed lines 
represent no treatment controls. 
 
Fig. 3: Impact of lycopene treatment on invasion of OV-MZ-6 and SKOV-3 cells. Both 
ovarian cancer cell lines did not respond to lycopene with significant changes in their invasive 
behavior; however, SKOV-3 cells showed a trend towards a reduced migration after 
treatment with 5.0 and 10.0 µM lycopene. Dashed lines represent no treatment controls. 
 
Fig. 4: Confocal laser scanning micrographs of OV-MZ-6 cells grown in GelMa-HA-
based hydrogels. A – G shows treatment with lycopene from day 1 to day 14; H – K shows 
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treatment with lycopene from day 7 to day 14. A) No treatment control, day 1: evenly 
distributed cells within the hydrogel; B) No treatment control, day 7: first spheroids begin to 
form; C) 7 days treatment with 0.5 µM lycopene: small spheroids visible; D) 7 days treatment 
with 5.0 µM lycopene: no visual difference to C; E) No treatment control, day 14: spheroids 
clearly visible; F) 14 days treatment with 0.5 µM lycopene: spheroids clearly visible; G) 14 
days treatment with 5.0 µM lycopene: no visual difference to F; H) Control group, day 14: 
spheroids clearly visible (as per E); I) 7 days treatment with 0.5 µM lycopene starting on day 
7; K) 7 days treatment with 5.0 µM lycopene starting on day 7. The confocal images show 
that there is no difference in spheroid size and number between both lycopene treatment 
regimes. Scale bars, 100 µm. 
 
Fig. 5: Scanning electron micrographs of OV-MZ-6 cells grown within GelMa-HA-based 
hydrogels. Cells are shown before (left side) and after (right side) lycopene treatment. Scale 
bars, 20 µm. 
 
Fig. 6a: Effect of lycopene treatment from day 1 until day 14 on proliferation and 
viability of OV-MZ-6 and SKOV-3 cells grown within GelMa-HA-based hydrogels. 
Proliferation and viability of OV-MZ-6 cells on day 7 was relatively unaffected, with a slight 
increase in viable cells and cell numbers after 14 days of treatment. Proliferation and viability 
of SKOV-3 cells significantly decreased after 7 days of treatment with 0.5 µM lycopene, but 
increased after 14 days as well. Asterisk indicates p<0.05. 
 
Fig. 6b: Effect of lycopene treatment from day 7 until day 14 on proliferation and 
viability of OV-MZ-6 and SKOV-3 cells grown within GelMa-HA-based hydrogels. Both, 
proliferation and viability of OV-MZ-6 and SKOV-3 cells was increased after treatment with 
lycopene, reaching significance only for viability of SKOV-3 cells. Asterisks indicate p<0.05.     
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Supporting Information 
Fig. S1: Viability of MDA-MB-231, LNCaP, PC-3, OV-MZ-6, and SKOV-3 cells after 
treatment with lycopene. U-shaped response curves were observed for every cell line and 
time point, showing a drop in cell viability at lycopene doses between 0.1 and 5.0 µM, 
followed by a sharp rise at 10.0 µM. Straight black lines represent no treatment controls. 
 
Fig. S2: Impact of lycopene treatment on proliferation of MDA-MB-231, LNCaP, PC-3, 
OV-MZ-6, and SKOV-3 cells. Cancer cell lines responded overall with decreasing growth 
rates at 4, 24, and 48 hrs of treatment. This was only significant for OV-MZ-6 cells after 24 
hrs treatment with 5.0 µM lycopene, as well as for MDA-MB-231 cells and LNCaP cells after 
48 hrs incubation with 0.5 µM lycopene. Exposure for 72 hrs led to rising proliferation rates of 
LNCaP, PC-3, and SKOV-3 cells. Dashed lines represent no treatment controls. Asterisk 
indicates p<0.05. 
 
Fig. S3: Effect of lycopene-containing and placebo beadlets on proliferation of OV-MZ-
6 cells. Proliferation of OV-MZ-6 cells was marginally reduced after treatment with lycopene 
in both treatment regimes (treatment from day 1 until day 14 as well as treatment from day 7 
until day 14). Placebo beadlets (upper line, filled circles) did not reduce cell proliferation in 
comparison to lycopene-containing beadlets. 
